Frontier IP portfolio firm Exscientia unveils collaboration with Roche as it raises US$26mln in funding round
The agreement will involve using Exscientia’s Centaur Chemis AI drug discovery platform to design pre-clinical drug candidates for the Swiss firm in return for up to 67mln Swiss francs in payments and support